Patients with significant cardiovascular disorders or with concomitant warfarin or equivalent vitamin K antagonist treatment were excluded from clinical trials [11, 12, 15], and limited data are available for this population, despite their relevance given the known effects of first-generation BTK inhibitors. This evidence concerns the gene BTK and cardiovascular disorder.